Having trouble accessing articles? Reset your cache.

OGX-427: Phase II started

OncoGenex began a 12-week, open-label, Canadian Phase II trial to evaluate twice-daily 5

Read the full 130 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE